Plague in depth.

Overview

Plague is a life-threatening zoonotic bacterial disease caused by Yersinia pestis, a gram-negative bacterium. It is transmitted to humans primarily through the bite of infected fleas that have fed on infected rodents (especially rats), or through direct contact with infected animals. Plague is responsible for three of history's most devastating pandemics — the Plague of Justinian (541–549 AD), the Black Death (1347–1353), and the Third Pandemic (1855–1960) — collectively killing hundreds of millions of people. Despite its apocalyptic history, plague remains very much present today, with 1,000–3,000 cases reported annually, primarily in Madagascar, the Democratic Republic of Congo, and parts of the Americas and Asia.

Three clinical forms of plague exist: bubonic (most common, ~80–90% of cases), septicemic, and pneumonic. Without treatment, bubonic plague has a case fatality rate of 30–60%; pneumonic plague (the form that spreads person-to-person via respiratory droplets) approaches 100% mortality if not treated within hours of symptom onset. With prompt antibiotic treatment, overall plague CFR falls to approximately 10%. The availability of effective antibiotics means plague is no longer an existential threat — but delayed diagnosis and treatment remain deadly.

History & Origin

Yersinia pestis evolved from Yersinia pseudotuberculosis about 5,000–10,000 years ago, acquiring the plasmids that enable flea-borne transmission and systemic virulence. The three great plague pandemics have permanently shaped human history, society, and genetics. The First Pandemic (Justinianic Plague, 541 AD) contributed to the decline of the Eastern Roman Empire. The Black Death (1347–1353) killed 30–60% of Europe's population — an estimated 50 million people — fundamentally transforming European society, labor markets, and religious institutions. The Third Pandemic originated in Yunnan, China in 1855, spread globally via shipping routes, and established plague in rodent reservoirs across the Americas, southern Africa, and Central Asia — where it persists today.

Alexandre Yersin identified the causative bacterium in 1894 during the Hong Kong epidemic (Paul-Louis Simond demonstrated flea transmission in 1898). The first plague vaccine was developed by Waldemar Haffkine in 1897. Streptomycin's discovery in 1943 transformed plague treatment — dramatically reducing mortality when treatment is prompt.

Transmission

• Flea bite (most common): Infected fleas (primarily Xenopsylla cheopis, the Oriental rat flea) regurgitate Y. pestis into bite wounds when feeding. Fleas become infected by feeding on bacteremic rodents.
• Direct contact with infected animals: Handling infected rodents, lagomorphs (rabbits, hares), or their carcasses. Hunters and veterinarians at risk. Domestic cats with pneumonic plague can transmit to owners.
• Person-to-person (pneumonic plague only): Respiratory droplets from patients with pneumonic plague; requires prolonged close contact (<2 meters); potential for hospital outbreaks without proper PPE.
• Contaminated material: Contact with plague-infected materials (tissues, bodily fluids). Rare but documented.
• Wildlife reservoir: Plague is maintained in nature by cycles between fleas and rodent populations (prairie dogs, squirrels, rats, gerbils). Human cases occur at the interface of human activity with enzootic rodent populations.

Clinical Forms & Symptoms

Diagnosis

• Culture: Blood culture, bubo aspirate culture, sputum culture (pneumonic plague). Y. pestis grows on standard laboratory media but must be handled in BSL-2 or BSL-3 containment. Notify laboratory immediately if plague suspected.
• Rapid diagnostic test (RDT): F1-antigen RDT — WHO-recommended; results in 15 minutes; used in field settings in Madagascar. High sensitivity and specificity.
• PCR: Highly sensitive; can detect Y. pestis from bubo aspirate, blood, sputum; useful when culture is negative (e.g., pre-antibiotic); reference standard for confirmation.
• Serology (passive hemagglutination): 4-fold rise in F1-antigen antibody titers between acute and convalescent sera; used for retrospective diagnosis and surveillance.
• Gram stain: Bubo aspirate smear shows characteristic "safety-pin" bipolar staining gram-negative coccobacilli — suggestive but not definitive.

Treatment

Plague is highly treatable with antibiotics if started promptly. For pneumonic plague, every hour of delay dramatically increases mortality — treatment must begin empirically without waiting for culture results.

• Streptomycin: WHO first-line; IM injection; 10 days. Most clinical experience; not available in all countries.
• Gentamicin: Equivalent efficacy to streptomycin; widely available; IV or IM; preferred in some settings.
• Doxycycline: Oral option for bubonic plague; also used for post-exposure prophylaxis.
• Ciprofloxacin: Alternative; particularly useful where other drugs unavailable; effective in animal models and case series.
• Chloramphenicol: Preferred for plague meningitis (CNS penetration); also for plague during pregnancy.
• Duration: 10–14 days. Buboes may take weeks to resolve even with treatment.
• Post-exposure prophylaxis: Contacts of pneumonic plague patients should receive 7 days of doxycycline or ciprofloxacin.
• Supportive care: IV fluids, vasopressors for shock; mechanical ventilation if respiratory failure; careful fluid balance.

Prevention & Control

• Flea control: Insecticide application to rodent burrows and human dwellings; avoiding contact with sick or dead rodents; flea repellent (DEET) in endemic areas.
• Rodent control: Do not disturb rodent burrows; remove food sources near human habitations; do not handle sick or dead wildlife without protective equipment.
• PPE for healthcare workers: Droplet and contact precautions for bubonic/septicemic plague; airborne precautions (N95 respirator, face shield, gown, gloves) for pneumonic plague.
• Post-exposure prophylaxis: 7-day course of antibiotics for contacts of pneumonic plague patients or people with known flea exposure in outbreak settings.
• Vaccine: A killed whole-cell vaccine was historically used (discontinued, no longer commercially available). A subunit (F1+V antigen) vaccine has shown efficacy in animals and is in Phase 2 human trials; no currently licensed plague vaccine is available internationally.
• Surveillance: Active rodent and flea surveillance in enzootic areas; rapid reporting of human cases; field investigation of rodent die-offs (epizootics often precede human cases).

Global Impact & Modern Outbreaks

Plague persists in established enzootic foci on every inhabited continent except Australia and Europe. Madagascar is the world's most plague-affected country, reporting 200–600 cases annually — including regular outbreaks of pneumonic plague. A major pneumonic plague outbreak in Madagascar in 2017 caused 2,417 suspected cases and 209 deaths, including spread to urban Antananarivo.

In the USA, plague is endemic in the western states (New Mexico, Arizona, Colorado, California), with an average of 7 human cases annually (range 1–17). American cases are typically bubonic, acquired through contact with prairie dogs, ground squirrels, or their fleas. The most recent US deaths occurred in 2015 (4 deaths) and occasionally thereafter. Global case numbers of 1,000–3,000 annually represent a massive reduction from historical levels, but the risk is not zero — particularly in conflict zones with degraded public health infrastructure.

Bioterrorism concern: Y. pestis is classified as a Category A bioterrorism agent by the CDC, reflecting its potential for mass casualties if weaponized (especially as aerosolized pneumonic plague). International biological weapons conventions prohibit its weaponization, but historical military programs (Soviet Biopreparat) developed plague strains with antibiotic resistance.

Frequently Asked Questions

Sources & Citations